Search Results for 23andme

The weekend read: why SPACs came, went, and failed in digital health–the Halle Tecco analysis/memorial service; why OpenAI is going to be a bad, bad business

...spectacularly, others with a whimper as they’ve failed, one after the other: 23andMe, Cano Health, Babylon Health, Nuvo, Pear, others 26.1% were acquired well below their SPAC entry price: Sharecare, SOC Telemed, Akili and others. The only exception: Augmedix, with a $40 million SPAC valuation, was bought for $139 million by Commure. (Commure is backed by General Catalyst and Andreessen Horowitz; Commure/Athelas itself is an interesting and complex story.) 39.1% are still in business but trading below their SPAC entry price. A number flirted with the Devil of Demise and are recovering: Clover Health, Owlet (baby monitors), Butterfly (ultrasound POC),... Continue Reading

Rock Health’s digital health Q1: more money, fewer deals, more additions and partnerships in ‘leapfrogging’

...tech as the market changes or better tech emerges. Channel Partnerships. Companies, by adding partners, add capability at low cost and reach, though the logistics of partnering, the integration cost and quality of service aren’t easy lifts. Engaging Disruptors. Companies invested in certain standard processes can expand by allying with their disruptors, versus viewing them as competitors. What’s not mentioned in the report are the high profile failures this quarter: 23andMe’s bankruptcy, Walgreens’ sale to Sycamore Partners, and Veradigm’s failure to sell itself. Given the past few months, we’ll be doing a lot of ’embracing uncertainty’ this year! Also FierceHealthcare... Continue Reading

23andMe’s slim list of prospective buyers–who must uphold privacy policies, according to the FTC. But what about that survey information? *Updated*

Barely a week later, but only a few buyers are lining up for 23andMe’s parts. The future of the bits and pieces of 23andMe and their 15 million customers apparently are in the Magic 8 Ball’s response class: “reply hazy, try again” and “cannot predict now”. Not entirely surprising is the lack of vigorous and financially competitive interest in them. Fortune counted the interested parties at only three, plus unsurprisingly, their controlling shareholder Anne Wojcicki. Here’s their rundown: Nucleus Genomics. This isn’t a surprise as their founder, Kian Sadeghi, had posted an article about their pass at 23andMe on Substack... Continue Reading

Weekend reading: 23andMe updates, a view at variance from the former co-founder, and a deeper historical analysis

...TTA summary of the bankruptcy 24-26 March This Editor likened the 23andMe implosion to that of Theranos–a watershed event that forces a rethinking of how we treat the privacy of customer medical data not covered by HIPAA, such as genetic data, as we approach (or try to approach) the mountain called ‘personalized medicine’. 23andMe’s co-founder, Linda Avey, essayed in LinkedIn yesterday that 23andMe was a missed opportunity to create a grand genomic dataset that would combine blood work, deeper gene sequencing, and wearable date culminating into actionable insights. The data is now fragmented among many holders. In her conclusion, she... Continue Reading

Breaking: 23andMe files for Chapter 11 bankruptcy–whither customer data and security? An impact similar to Theranos?

The exploding plastic inevitable comes to its inevitable end. 23andMe’s board filed for a Chapter 11 bankruptcy with the Eastern District of Missouri (!) Federal bankruptcy court on Sunday night (Case 25-40976). Anne Wojcicki, CEO, 49% controlling shareholder, and board member, stepped down from the CEO position, but remains on the board. Interim CEO is Joseph Selsavage, 23andMe’s chief financial and accounting officer, according to their SEC Form 8-K filing. In their announcement, 23andMe will, with court approval, actively solicit asset sales over a 45 day period. Anne Wojcicki’s final non-binding proposals on 10 and 11 March were rejected by... Continue Reading

Update: Wojcicki increases 23andMe per share offer to $2.94 from $0.41–but there’s three contingency ‘catches’, and more

Will the 23andMe board go for this offer? Can this bulb be relit? There are two additional SEC Schedule D amended filings (#11 and #12) made on 10 and 11 March that sweeten the $0.41 per share all-cash deal just rejected by the 23andMe board [TTA 4 Mar]. The total value is now increased to a total of $2.94–but the additional $2.53 per share is made up of ‘catches’ called ‘contingent value rights’ or CVRs. These payments to shareholders are not immediate, but dependent on future performance and revenue milestones. In addition, and going unmentioned, are $50 million in operational... Continue Reading

Breaking: 23andMe sale bids slide from $2.53 per share to $0.41 to none in 11 days, as board rejects CEO’s offer

23andMe’s future growing dimmer by the day. Last week before Friday, 23andMe seemed to have a fighting chance. The 20 February Schedule 13D filing proposed a take-private offer for $2.53 per share, or $74.7 million, a small premium above their Nasdaq CM trading price, with CEO and controlling shareholder Anne Wojcicki joined by investor New Mountain Capital (NMC) [TTA 27 Feb]. Evidently that offer went sideways before the board of directors’ Special Committee could even consider it. By Friday 28 February, a week later, New Mountain withdrew from the acquisition bid for unspecified reasons. On Sunday 2 March, Ms. Wojcicki... Continue Reading

These just in: drug compounders sue FDA over semaglutide scarcity removal; Sycamore’s Walgreens buy plans begin to show

...and Wegovy [TTA 25 Feb]. The compounding was a boon for telehealth providers such as Hims and Hers, Ro, 23andMe (Lemonaid), Future Health, Weight Watchers, Lark, and many others. It allowed them to customize injectable formulations for customers on weight loss programs at a far lower cost than standard branded products. The FDA allows this only during times of shortage (compounded by Section 503A pharmacies and Section 503B outsourcing facilities as “essential copies” of FDA-approved drugs). Exceptions are also made if the standard drug is in some way inappropriate for the patient who then medically requires a customized version, e.g.... Continue Reading

23andMe gets a $74.7M offer from Wojcicki and New Mountain Capital–this time for real?

...be countered by others is not known, but a safe assumption is that this will be the only one on the table. Ms. Wojcicki has effective majority control, confirmed in the Schedule 13D filing as 20% of Class A common stock and 69.4% of Class B common stock. Reportedly this gives her 49.99% of the voting power. Both Ms. Wojcicki and New Mountain are offering secured debt financing to fund 23andMe’s operations through the transaction’s closing, As a result, other offers are not likely in this Editor’s estimation. No timing is reported or comment available from 23andMe. CNBC, Lawyer Monthly... Continue Reading

News roundup: DOJ investigating UHG on Medicare Advantage billing upcoding; Teladoc’s BetterHelp therapists using AI?–a short seller alleges; Hims whacked by FDA ending compounded GLP-1s (updated); some fired FDA staffers in CDRH reinstated

...approximate or customize the branded versions of these drugs for weight loss, are now prohibited from doing so. They have till April or May to transition to branded injectable versions. This affects the bottom line of all these telemedicine prescribers such as Ro, Weight Watchers, Future Health (a heavy local radio advertiser), 23andMe, and Hims & Hers. Hims, the showiest in class, took a breathtaking 25% hit on their stock between Friday and Monday. It is not only cost of branded drugs but also that so many competitors have jumped into the field, creating another shortage of the branded drugs,... Continue Reading